Recent Insider Transactions • Jun 28
Independent Non-Executive Chairman recently bought AU$101k worth of stock On the 24th of June, James Hall bought around 51k shares on-market at roughly AU$1.96 per share. This transaction amounted to 23% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of AU$163k worth in shares. Board Change • May 20
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Radiologist Executive Director Manish Mittal was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • May 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Radiologist Executive Director Manish Mittal was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Dec 24
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Radiologist Executive Director Manish Mittal was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Duyuru • Sep 02
Integral Diagnostics Limited, Annual General Meeting, Oct 31, 2025 Integral Diagnostics Limited, Annual General Meeting, Oct 31, 2025. Declared Dividend • Aug 28
Final dividend increased to AU$0.04 Dividend of AU$0.04 is 21% higher than last year. Ex-date: 29th August 2025 Payment date: 31st October 2025 Dividend yield will be 2.2%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is not covered by earnings (427% earnings payout ratio) nor is it covered by cash flows (173% cash payout ratio). The dividend has increased by an average of 5.5% per year over the past 9 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 374% to bring the payout ratio under control. EPS is expected to grow by 126% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio. Reported Earnings • Aug 26
Full year 2025 earnings released: EPS: AU$0.016 (vs AU$0.26 loss in FY 2024) Full year 2025 results: EPS: AU$0.016 (up from AU$0.26 loss in FY 2024). Revenue: AU$629.1m (up 34% from FY 2024). Net income: AU$4.67m (up AU$65.4m from FY 2024). Profit margin: 0.7% (up from net loss in FY 2024). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare industry in Australia. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Board Change • Aug 18
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Radiologist Executive Director Manish Mittal was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Duyuru • Mar 11
Private Equity Players Reportedly Keep Close Tabs on Integral Diagnostics Integral Diagnostics Limited (ASX:IDX) is believed once again to be in the spotlight for private equity buyers after its share price took a hit after its half year results, trimming its market value to $837 million. Sources say the diagnostic imaging company is constantly being assessed by private equity firms, eager to increase exposure to healthcare. But right now it is looking like a good buying opportunity and is grabbing attention. Obvious suitors would be the underbidders from the sale last year of the Healius diagnostic imaging group that sold for $965 million to Affinity Equity Partners. The underbidders were TPG Capital, L.P. and Pacific Equity Partners. Duyuru • Feb 05
Integral Diagnostics Limited Appoints Manish Mittal to the Board as Radiologist Executive Director Integral Diagnostics Limited announced the appointment of experienced IDX radiologist Dr. Manish Mittal (MBBS (Hons), MD, FRCR, FRANZCR, FSCMR) to the Board as a Radiologist Executive Director with effect from 5 February 2025. Mittal is a Fellow of both the UK and Australia & New Zealand Royal Colleges of Radiology with a professional focus on MRI, including musculoskeletal, prostrate and cardiac imaging in addition to extensive experience in neuroradiology and abdominal radiology. Dr. Mittal has worked within IDX and its precursor businesses for over 18 years and held senior clinical governance and leadership roles across a number of IDX business units. He is currently the Clinical Director of IDXt, IDX's fast growing teleradiology business, and also a consultant radiologist at Gold Coast University Hospital. Board Change • Feb 04
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Laura McBain was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Duyuru • Jan 20
Integral Diagnostics Limited Announces Company Secretary Changes In accordance with Listing Rule 3.16, Integral Diagnostics Limited announced that effective 20 January 2025, Mr. John Merity has been appointed as company's permanent Company Secretary, continuing from the interim role to which he was appointed on 7 June 2024. Also effective from 20 January 2025, Ms Nikki Dalla Valle will relinquish her role as Company Secretary, continuing in her role as General Counsel, responsible for Legal and Risk. New Risk • Jan 11
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 59% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Shareholders have been substantially diluted in the past year (59% increase in shares outstanding). Board Change • Jan 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Laura McBain was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Duyuru • Dec 20
Integral Diagnostics Limited Announces Board Appointments Integral Diagnostics Limited has appointed the following Capitol Directors to the Integral Board with effect from 20 December 2024. Laura McBain, as Non-Executive Director; and Dr Kevin Shaw, as Non-Executive Director. Ms McBain has extensive executive and leadership experience having held roles as Managing Director at Bellamy's Australia, Maggie Beer Holdings and Lark Distilling. Dr Shaw is a highly qualified radiologist with fellowship training in MRI. He is the Director of Medical Imaging at University Hospital Geelong. Duyuru • Dec 12
Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ). Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million on June 17, 2024. The consideration consists of common equity of Integral Diagnostics Limited at a ratio of 0.12849 per common equity of Capitol Health Limited. As per the transaction, Integral and Capitol shareholders would be expected to own approximately 63% and 37% respectively of the combined entity. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders, due diligence investigation and subject to court approval. As of October 29, 2024, Capitol announces that the Federal Court of Australia (Court) has today made orders to postpone the date of the Scheme Meeting at which Capitol Shareholders will vote on the proposed Scheme. The Scheme Meeting has been postponed from October 31, 2024 to December 2, 2024. The date for the Second Court Hearing has been changed from November 1, 2024 to December 4, 2024. As a consequence of the Court orders postponing the Scheme Meeting, the indicative Effective Date on which the Scheme comes into effect and is binding on Capitol Shareholders will be on December 5, 2024. As of November 25, 2024, the Scheme is subject to a number of conditions precedent, including that IDX has received informal merger clearance from the Australian Competition and Consumer Commission (ACCC). The ACCC has delayed its proposed decision date in relation to the Competition Approval to allow the ACCC to consider the divestment. The ACCC has not yet announced a new proposed date of its decision in relation to the Competition Approval, although Capitol anticipates that the decision date will occur in December 2024. The Scheme Meeting will proceed on December 2, 2024. As of December 10, 2024, the Australian Competition and Consumer Commission confirmed that it will not oppose the merger and the Federal Court of Australia made orders approving the Scheme. The deal is expected to complete on December 11, 2024.
Barrenjoey Capital Partners and Jefferies (Australia) Pty Ltd acted as financial advisors to Integral Diagnostics Limited (ASX:IDX) while Citigroup Global Markets Australia Pty Limited acted as a financial advisor to Capitol Health Limited. Herbert Smith Freehills acted as a legal advisor to Integral Diagnostics Limited while Maddocks Inc. Pty Ltd. provided legal assistance to Capitol Health Limited. KPMG Financial Advisory Services (Australia) Pty Limited provided fairness opinion in the deal to Capitol Health Limited. Computershare Investor Services Pty Limited acted as registrar to Integral Diagnostics Limited and Capitol Health Limited.
Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ) on December 11, 2024. Reported Earnings • Aug 29
Full year 2024 earnings released: AU$0.26 loss per share (vs AU$0.11 profit in FY 2023) Full year 2024 results: AU$0.26 loss per share (down from AU$0.11 profit in FY 2023). Revenue: AU$469.7m (up 6.6% from FY 2023). Net loss: AU$60.7m (down 342% from profit in FY 2023). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Healthcare industry in Australia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 85 percentage points per year, which is a significant difference in performance. Duyuru • Jun 19
Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million. Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million on June 17, 2024. The consideration consists of common equity of Integral Diagnostics Limited at a ratio of 0.12849 per common equity of Capitol Health Limited. As per the transaction, Integral and Capitol shareholders would be expected to own
approximately 63% and 37% respectively of the combined entity. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders, due diligence investigation and subject to court approval. Barrenjoey Capital Partners and Jefferies (Australia) Pty Ltd acted as financial advisors and Herbert Smith Freehills acted as legal advisor to Integral Diagnostics Limited. Citigroup Global Markets Australia Pty Limited acted as financial advisor and Maddocks Inc. Pty Ltd. acted as legal advisor to Capitol Health Limited. Declared Dividend • Feb 22
First half dividend of AU$0.025 announced Shareholders will receive a dividend of AU$0.025. Ex-date: 29th February 2024 Payment date: 2nd April 2024 Dividend yield will be 2.8%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (70% cash payout ratio). The dividend has increased by an average of 6.0% per year over the past 7 years. However, payments have been volatile during that time. Reported Earnings • Feb 22
First half 2024 earnings released: AU$0.29 loss per share (vs AU$0.069 profit in 1H 2023) First half 2024 results: AU$0.29 loss per share (down from AU$0.069 profit in 1H 2023). Revenue: AU$231.3m (up 7.2% from 1H 2023). Net loss: AU$66.8m (down AU$82.9m from profit in 1H 2023). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Healthcare industry in Australia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance. Duyuru • Feb 07
IDX™ Announces Appointment of Scott Paterson as Worldwide CFO IDX™ announced the appointment of industry veteran Scott Paterson as chief financial officer. In his role, Paterson will partner with Worldwide CEO Myles Peacock and the IDX Board of Directors to continue the growth and evolution of the business. Paterson has held various senior finance roles for over 15 years, with many spent in marketing content, communications and technology. Prior to joining IDX, Paterson was CFO of private equity-backed TREND Networks, where he played a key role in the growth of the organization. He subsequently led the business through a private equity exit. Prior to TREND Networks, Paterson was group financial controller at Guinness World Records, where he was integral in transforming the business from its publishing core to a more diversified media enterprise focused on content creation and both digital and broadcast media. Paterson’s appointment is effective immediately. Duyuru • Dec 12
Integral Diagnostics Limited Announces Change of Company Secretary Integral Diagnostics Limited advised that Kirsty Lally has resigned as Company Secretary of Integral Diagnostics Limited effective 14 December 2023. Nikki Dalla Valle has been appointed as Company Secretary effective 14 December 2023 and is the person nominated under Listing Rule 12.6 for communication with ASX in relation to Listing Rule matters. Recent Insider Transactions • Dec 06
Independent Non-Executive Director recently bought AU$258k worth of stock On the 30th of November, James Hall bought around 150k shares on-market at roughly AU$1.72 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$430k more in shares than they have sold in the last 12 months. Duyuru • Nov 30
Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023 Integral Diagnostics Limited announced resignation of Helen Kurincic as director effective 29 November 2023. Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment deteriorates as stock falls 27% After last week's 27% share price decline to AU$1.94, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 20x in the Healthcare industry in Australia. Total loss to shareholders of 51% over the past three years. Duyuru • Sep 28
Integral Diagnostics Limited Appoints Toby Hall as Director Integral Diagnostics Limited announced that the appointment of Toby Hall as director. The date of appointment is September 28, 2023. Duyuru • Sep 25
Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023 Integral Diagnostics Limited declared a fully franked final dividend of AUD 0.03500000 per ordinary share for the six months ended June 30, 2023 with a record date of 1 September 2023. Ex date of August 31, 2023.Payable on 4 October 2023. Reported Earnings • Aug 30
Full year 2023 earnings released: EPS: AU$0.11 (vs AU$0.07 in FY 2022) Full year 2023 results: EPS: AU$0.11 (up from AU$0.07 in FY 2022). Revenue: AU$440.8m (up 22% from FY 2022). Net income: AU$25.0m (up 72% from FY 2022). Profit margin: 5.7% (up from 4.0% in FY 2022). Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Healthcare industry in Australia. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Duyuru • Aug 28
Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023 On 28 August 2023 the directors of Integral Diagnostics Limited declared a fully franked final dividend of 3.5 cents per ordinary share with a record date of 1 September 2023 to be paid on 4 October 2023. Duyuru • Aug 10
Integral Diagnostics Limited Announces Board Changes Integral Diagnostics Limited announced the appointment of Ingrid Player as an independent non-executive Director, effective 29 August 2023. Ms. Player has more than 20 years' experience in the healthcare industry, gained from leadership roles across the private, public and not for profit sectors. In her executive career, Ms. Player was Group Executive - Legal, Governance and Sustainability at Healthscope. As a qualified lawyer, she previously worked in private legal practice in Australia and Europe specialising in corporate law, M&A and capital markets. She brings to the Board extensive experience in leveraging corporate transactions and major capital projects to achieve strategic outcomes, as well as skills in risk management, government relations, sustainability and corporate governance. She currently serves as a Non-Executive Director of Cleanaway Management Ltd, Cogstate Ltd, Epworth Foundation and HealthShare Victoria. She holds a Bachelor of Laws (Hons) and Bachelor of Economics from Monash University and is a member of the AICD. She will be appointed a Member of the Audit, Risk & Compliance Committee and a Member of the People, Culture & Remuneration Committee. The company announced the resignation of John Atkin as an independent non-executive Director effective 31 August 2023. The company also announced the resignation of Dr. Nazar Bokani, an Executive Radiologist Director effective 9 August 2023. Dr. Bokani joined the Board on 26 April 2021 and is relocating overseas to be closer to his family. Upcoming Dividend • Feb 23
Upcoming dividend of AU$0.025 per share at 2.0% yield Eligible shareholders must have bought the stock before 02 March 2023. Payment date: 04 April 2023. Payout ratio is a comfortable 60% and the cash payout ratio is 85%. Trailing yield: 2.0%. Lower than top quartile of Australian dividend payers (6.9%). Lower than average of industry peers (2.7%). Reported Earnings • Feb 18
First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022) First half 2023 results: EPS: AU$0.069 (up from AU$0.051 in 1H 2022). Revenue: AU$215.7m (up 19% from 1H 2022). Net income: AU$16.1m (up 58% from 1H 2022). Profit margin: 7.5% (up from 5.6% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Australia. Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 14% per year. Duyuru • Feb 18
Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023 Integral Diagnostics Limited announced an ordinary dividend of AUD 0.025000 for the six months ended December 31, 2022. The ex-date is March 2, 2023, record date is March 3, 2023, and payment date is April 4, 2023. Buying Opportunity • Feb 17
Now 21% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be AU$3.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has declined by 9.6%. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings is also forecast to grow by 23% per annum over the same time period. Duyuru • Feb 16
Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023 Integral Diagnostics Limited announced that they will report first half, 2023 results on Feb 17, 2023 Recent Insider Transactions • Sep 06
Independent Non-Executive Director recently bought AU$114k worth of stock On the 30th of August, Andrew Fay bought around 40k shares on-market at roughly AU$2.86 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$199k more in shares than they have sold in the last 12 months. Reported Earnings • Aug 29
Full year 2022 earnings released Full year 2022 results: Revenue: AU$361.0m (up 2.9% from FY 2021). Net income: AU$14.6m (down 53% from FY 2021). Profit margin: 4.0% (down from 8.9% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 21% while the Healthcare industry in Australia is not expected to grow. Valuation Update With 7 Day Price Move • Aug 02
Investor sentiment improved over the past week After last week's 17% share price gain to AU$3.23, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 19x in the Healthcare industry in Australia. Total returns to shareholders of 4.8% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at AU$5.15 per share. Buying Opportunity • Jul 02
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 23%. The fair value is estimated to be AU$3.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 4.4%. For the next 3 years, revenue is forecast to grow by 10.0% per annum. Earnings is also forecast to grow by 21% per annum over the same time period. Recent Insider Transactions • Mar 04
Executive Director recently bought AU$70k worth of stock On the 28th of February, Jacqueline Milne bought around 20k shares on-market at roughly AU$3.50 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Feb 25
First half 2022 earnings: EPS in line with analyst expectations despite revenue beat First half 2022 results: EPS: AU$0.051 (down from AU$0.10 in 1H 2021). Revenue: AU$181.5m (up 5.7% from 1H 2021). Net income: AU$10.2m (down 49% from 1H 2021). Profit margin: 5.6% (down from 12% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.3%. Over the next year, revenue is forecast to grow 12%, compared to a 3.0% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Sep 02
Investor sentiment deteriorated over the past week After last week's 15% share price decline to AU$4.57, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 19x in the Healthcare industry in Australia. Total returns to shareholders of 91% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at AU$6.10 per share. Reported Earnings • Aug 28
Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.12 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$351.0m (up 27% from FY 2020). Net income: AU$31.3m (up 36% from FY 2020). Profit margin: 8.9% (up from 8.4% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth. Executive Departure • Mar 03
Executive Director has left the company On the 1st of March, Chien Ho's tenure in the role of Executive Director ended. As of December 2020, Chien personally held 2.07m shares (AU$9.0m worth at the time). Chien is the only executive to leave the company over the last 12 months. Reported Earnings • Feb 23
First half 2021 earnings released: EPS AU$0.10 (vs AU$0.062 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$171.7m (up 30% from 1H 2020). Net income: AU$19.9m (up 83% from 1H 2020). Profit margin: 12% (up from 8.2% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Feb 23
Revenue beats expectations Revenue exceeded analyst estimates by 9.0%. Over the next year, revenue is forecast to grow 14%, compared to a 7.0% growth forecast for the Healthcare industry in Australia. Duyuru • Feb 02
Integral Diagnostics Limited to Report First Half, 2021 Results on Feb 22, 2021 Integral Diagnostics Limited announced that they will report first half, 2021 results on Feb 22, 2021 Is New 90 Day High Low • Jan 25
New 90-day high: AU$4.48 The company is up 9.0% from its price of AU$4.12 on 28 October 2020. The Australian market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$6.81 per share. Is New 90 Day High Low • Nov 12
New 90-day high: AU$4.42 The company is up 17% from its price of AU$3.78 on 14 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$6.10 per share. Recent Insider Transactions • Nov 10
Executive Director recently sold AU$266k worth of stock On the 6th of November, Chien Ho sold around 60k shares on-market at roughly AU$4.42 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of AU$363k more than they bought in the last 12 months. Recent Insider Transactions • Sep 26
Executive Director recently sold AU$123k worth of stock On the 18th of September, Chien Ho sold around 30k shares on-market at roughly AU$4.10 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of AU$266k more than they bought in the last 12 months. Duyuru • Sep 15
Integral Diagnostics Limited (ASX:IDX) agreed to acquire Ascot Radiology Limited for NZD 54 million. Integral Diagnostics Limited (ASX:IDX) agreed to acquire Ascot Radiology Limited for NZD 54 million on June 10, 2020. The consideration is on a cash and debt free basis. Integral Diagnostics Limited will pay NZD 40 million in cash and NZD 10 million in shares to 17 doctors at completion. Integral Diagnostics Limited will issue 2.9 million shares as consideration on September 1, 2020. The scrip consideration will be subject to escrow arrangements. The escrowed shares will be released in equal tranches on the third, fourth and fifth anniversaries of the share issuance date. An earn out consideration of NZD 2.8 million will be paid subject to earnings before interest, taxes, depreciation and amortization performance hurdles linked to the performance of the combined IDX business in New Zealand. The transaction will be funded by existing debt facilities of AUD 75 million (NZD 80.02 million). The Board of Ascot Radiology Limited will join Integral Diagnostics Limited. The transaction is subject to satisfaction of customary conditions. The acquisition is expected to be completed in September 2020. As of August 25, 2020, The acquisition is expected to be completed on September 1, 2020. The transaction is expected to be accretive in the first year following the acquisition. Raji Azzam of Herbert Smith Freehills acted as legal advisor to Integral Diagnostics Limited. Minter Ellison Rudd Watts acted as legal advisor for sellers. Allier Capital Pty Ltd acted as financial advisor to Ascot Radiology Limited. Duyuru • Sep 01
Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Ascot Radiology Limited. Integral Diagnostics Limited (ASX:IDX) agreed to acquire Ascot Radiology Limited for NZD 54 million on June 10, 2020. The consideration is on a cash and debt free basis. Integral Diagnostics Limited will pay NZD 40 million in cash and NZD 10 million in shares to 17 doctors at completion. Integral Diagnostics Limited will issue 2.9 million shares as consideration on September 1, 2020. The scrip consideration will be subject to escrow arrangements. The escrowed shares will be released in equal tranches on the third, fourth and fifth anniversaries of the share issuance date. An earn out consideration of NZD 2.8 million will be paid subject to earnings before interest, taxes, depreciation and amortization performance hurdles linked to the performance of the combined IDX business in New Zealand. The transaction will be funded by existing debt facilities of AUD 75 million (NZD 80.02 million). The Board of Ascot Radiology Limited will join Integral Diagnostics Limited. The transaction is subject to satisfaction of customary conditions. The acquisition is expected to be completed in September 2020. As of August 25, 2020, The acquisition is expected to be completed on September 1, 2020. The transaction is expected to be accretive in the first year following the acquisition. Raji Azzam of Herbert Smith Freehills acted as legal advisor to Integral Diagnostics Limited. Minter Ellison Rudd Watts acted as legal advisor for sellers.
Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Ascot Radiology Limited on September 1, 2020. 
